PharmAI

Executive Summary

PharmAI Discovery is a Berlin-based biotech leveraging deterministic AI, medicinal chemistry, and radiolabeling to transform challenging protein–protein interactions (PPIs) into first-in-class therapeutics and precision theranostics. Founded in 2019, the company’s end-to-end platform screens up to 300 million compounds, optimizes leads, and validates candidates in vivo, aiming to deliver IND-ready assets 18 months faster than traditional approaches with a 10× higher hit rate. By targeting PPIs—a class of targets historically considered undruggable—PharmAI addresses a critical unmet need in oncology, neurodegenerative diseases, and beyond, potentially unlocking a new wave of precision medicines. The company’s integrated approach combines computational power with experimental validation, reducing attrition and accelerating timelines in a sector where speed and accuracy are paramount. With a pre-clinical stage and a focus on first-in-class molecules, PharmAI occupies a niche at the intersection of AI-driven drug discovery and theranostics, offering a compelling value proposition for potential partners and investors. If successful, its platform could significantly lower the cost and risk of developing drugs for difficult targets, positioning it as a key player in the next generation of biopharmaceutical innovation.

Upcoming Catalysts (preview)

• H2 2026Lead Optimization Completion for Lead PPI Program70% success
• 2027Initiation of IND-Enabling Studies60% success
• Late 2026Strategic Partnership with Large Pharma50% success